Logo_AIHTA
  • English
            Menu_button
                                  Video
                                  Video: What is HTA?    
                                  • Home
                                  • News

                                  News

                                  Leiste32


                                  Welcome to the homepage of AIHTA!

                                  AIHTA is an academic non-profit institute. At our website we wish to present our research and give support for health care decision-making. Here all of our reports are available for free. For further information please contact the AIHTA team.

                                  In the News section you will find our most recent publications: newsletter, project-reports etc. Previous reports you might find via Research areas, Research projects and Repository.

                                  Subscribe to newsletter

                                  Newsletter

                                  Newsletter Archive

                                  Newsletter October 2013 | Nr. 121

                                  More...

                                  212

                                  Announcement

                                  Horizon Scanning in Onkology - Reports

                                  We are pleased to introduce two new HSO reports.

                                  DSD HSO No. 39
                                  Pomalidomide (Pomalyst®) for the ? 3rd-line therapy of patients with relapsed and refractory multiple myeloma

                                  DSD HSO No. 40
                                  Regorafenib (Stivarga®) for heavily pretreated patients with metastatic colorectal cancer (mCRC)

                                  More...

                                  Papsmear1

                                  Announcement

                                  Cervical cancer screening: p16/KI-67 Dual Stain test (CINtec® PLUS) in the triage of equivocal results or mild to moderate dysplasia in pap cytology

                                  Each year around 30 000 women in Austria receive a PAPIII or PAPIIID cytology result during routine cervical cancer screening. Roughly equivalent to ASC-US or LSIL cytology, the risk of progression to cancer for these patients is unclear and requires further diagnostic investigation: for many of the women the ensuing procedures and potential adverse effects turn out to be unnecessary. The p16/Ki-67 Dual Stain test (CINtec® PLUS) claims to improve the triage of these women. In a systematic review though we could not identify sufficient evidence to support the utility of the p16/Ki-67 Dual Stain test in the triage of equivocal or mild to moderate dysplasia results in Austria.

                                  Publication: LBI-HTA Project report No. 72: https://eprints.aihta.at/1009/

                                  Contact: Agnes Kisser

                                  More...

                                  Event archive

                                  033_20131030_j_preview

                                  Event

                                  „Biotech, Klinik, Public Health: Welche Forschung braucht unsere Gesundheit?“

                                  This info is available in german only

                                  More...

                                  Article

                                  Horizon Scanning of Medicines - Reports and Fact Sheets

                                  More...

                                  251

                                  Article

                                  Evaluation of individual medical procedures - Reports

                                  More...

                                  « < ... 41 42 43 44 45 > »
                                  Displaying results 441 to 446.
                                                                                                      Netzwerk
                                                                                                      • Ebm
                                                                                                      • Inahta
                                                                                                      Shareholder
                                                                                                      • Bmfg
                                                                                                      • Sv
                                                                                                      • Wgfond
                                                                                                      • Noe
                                                                                                      • Ooghfond
                                                                                                      • Ghls
                                                                                                      • Tirol
                                                                                                      • Vorarlberg
                                                                                                      • Kghfond
                                                                                                      • Ghpf
                                                                                                      • Burgef
                                                                                                                © 2025 HTA Austria - Austrian Institute for Health Technology Assessment GmbH. Alle Rechte vorbehalten.
                                                                                                                • Log in